BMO Capital initiated coverage of Neurogene with an Outperform rating and $65 price target. Most investors are new to “the Rett syndrome story,” which the firm calls a $2.5B opportunity made possible by breakthroughs in gene therapy. NGN-401 is a next-generation gene therapy and initial Phase 1/2 safety data was “robust,” says the analyst, who sees the focus as now the initial efficacy readout due in Q4.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene Releases Updated Corporate Presentation Online
- Neurogene negative reaction to competitor data ‘overblown,’ says William Blair
- Neurogene’s Rett Syndrome Trial Shows Promise
- Neurogene announces first patient dosed in high-dose cohort of NGN-401
- Neurogene initiated with an Outperform at Baird